EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A SynB1-conjugated antibody cocktail crosses the blood–brain barrier to produce a therapeutic effect on rabies

Zeheng Ren, Caiqian Wang, Haoran Wang, Qiong Wu, Qingxiu Hou, Xue Qi, Wenna He, Xiaoyu Zhang, Jiawu Wan, Zhen F Fu iD, Ming Zhou iD, Ling Zhao iD

Proceedings of the National Academy of Sciences · 30.12.2025 · 122 (52)

DOI: 10.1073/pnas.2516465122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 23.12.2025. Verfasst von Zeheng Ren und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Rabies, Rabies virus, Antibodies, Viral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rabies, caused by the neurotropic lyssavirus rabies virus (RABV), is nearly 100% fatal after symptom onset. A fundamental challenge for rabies therapy is that the blood–brain barrier (BBB) prevents peripherally administered neutralizing antibodies from entering the central nervous system (CNS) to clear the infection. In this study, we initially generated four human–mouse chimeric antibodies with preserved neutralizing potency against RABV to increase its translational potential. To achieve brain antibody delivery, we conjugated a lead chimeric antibody (7A3-H) to different cell-penetrating peptides with potential BBB-penetrating capacity (RVG, TGN, THR, and SynB1). In vivo fluorescence imaging revealed that SynB1 conjugation significantly outperformed conjugation with the other peptides in terms of BBB penetration for brain antibody delivery. Furthermore, a triple-antibody cocktail (targeting epitopes II/III/IV of RABV-G) conjugated to SynB1 resulted in 80% survival in mice infected with lethal challenge virus standard (CVS) or dog-originated rabies virus (DRV) strains when it was administered at 5 dpi (when CNS invasion and symptoms were evident). In contrast, the unconjugated cocktail provided only 20% (CVS) or 0% (DRV) survival. Together, these data demonstrated that SynB1-mediated BBB penetration dramatically improved the therapeutic efficacy of anti-RABV antibodies, enabling post-symptom rescue of rabies. This antibody–peptide conjugation strategy provides a proof of concept for advancing rabies therapy, specifically by leveraging peptide-mediated enhancement of BBB penetration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierRabiesRabies virusAntibodies, ViralAntibodies, NeutralizingAnimalsMiceHumansCell-Penetrating PeptidesFemaleCombined Antibody Therapeutics

Stichwörter der Autor:innen

CNS deliverySynB1 peptideantibody cocktail treatmentblood–brain barrier penetrationrabies therapy

Substanzen

Antibodies, ViralAntibodies, NeutralizingCell-Penetrating PeptidesCombined Antibody Therapeutics

Autor:innen und Institutionen

  • National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China.
  • Hubei Jiangxia Laboratory, Wuhan 430200, China.
  • Hubei Hongshan Laboratory, Wuhan 430070, China.
  • Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China.

ORCID-Profile: Zhen F Fu, Ming Zhou, Ling Zhao

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities)

Zitieren

APA

Ren, Z., Wang, C., Wang, H., Wu, Q., Hou, Q., Qi, X., He, W., Zhang, X., Wan, J., Fu, Z. F., Zhou, M., & Zhao, L. (2025). A SynB1-conjugated antibody cocktail crosses the blood–brain barrier to produce a therapeutic effect on rabies. Proceedings of the National Academy of Sciences, 122(52). https://doi.org/10.1073/pnas.2516465122

Vancouver

Ren Z, Wang C, Wang H, Wu Q, Hou Q, Qi X, et al. A SynB1-conjugated antibody cocktail crosses the blood–brain barrier to produce a therapeutic effect on rabies. Proceedings of the National Academy of Sciences. 2025;122(52). doi:10.1073/pnas.2516465122

BibTeX
@article{Ren2025,
  author = {Ren, Zeheng and Wang, Caiqian and Wang, Haoran and Wu, Qiong and Hou, Qingxiu and Qi, Xue and He, Wenna and Zhang, Xiaoyu and Wan, Jiawu and Fu, Zhen F and Zhou, Ming and Zhao, Ling},
  title = {A SynB1-conjugated antibody cocktail crosses the blood–brain barrier to produce a therapeutic effect on rabies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {52},
  doi = {10.1073/pnas.2516465122}
}
Kostenlos starten →